-
UPDATE: Oppenheimer Initiates Derma Sciences at Outperform
Wednesday, July 6, 2011 - 9:34am | 97Read More...Oppenheimer is out with its report today on Derma Sciences (NASDAQ: DSCI), initiating DSCI at Outperform. In a note to clients, Oppenheimer writes, "We are initiating coverage of Derma Sciences with an Outperform rating and 12-18 month price target of $21. We believe its lead pipeline candidate,...
-
Oppenheimer Initiates Derma Sciences At Outperform, $21 PT
Wednesday, July 6, 2011 - 6:57am | 24Read More...Oppenheimer has initiated coverage on Derma Sciences (NASDAQ: DSCI) with an Outperform rating and $21 price target.
